The differences reached statistical significance (retained after controlling for type I error) for IL-2 compared to all other groups, for IFN-γ, compared to MS patients, and for IL-6 compared to SC (Fig 2 and S1 Table). The gene discussed is IL6; the disease is myeloid sarcoma.